Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

Published:2006 Issue:3 Volume:53 Page:325-330
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

MAJIMA Takafumi¹²,KOMATSU Yasato²,DOI Kentaro¹,SHIGEMOTO Michika¹,TAKAGI Chieko¹,FUKAO Atsushi³,CORNERS Jerry⁴,NAKAO Kazuwa²

Affiliation:

1. Department of Endocrinology and Metabolism, Rakuwakai Otowa Hospital

2. Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine

3. Department of Psychosomatic Medicine, Rakuwakai Otowa Hospital

4. Medical Adviser, Rakuwakai Otowa Hospital

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.jstage.jst.go.jp/article/endocrj/53/3/53_3_325/_pdf

Reference26 articles.

1. Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

2. 2. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA (2001) Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134: 61-71.

3. 3. Stumvoll M, Haring HU (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34: 217-224.

4. 4. O'Moore-Sullivan TM, Prins JB (2002) Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust 176: 381-386.

5. 5. Edelman SV (2003) The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. Rev Cardiovasc Med 4: S29-37.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease;Diabetology International;2023-02-18

2. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study;Diabetes, Obesity and Metabolism;2022-06-09

3. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment;Frontiers in Cardiovascular Medicine;2021-09-07

4. Identification of an allosteric hotspot for additive activation of PPARγ in antidiabetic effects;Science Bulletin;2021-08

5. Impact of discontinuation of fish oil after pioglitazone–fish oil combination therapy in diabetic KK mice;The Journal of Nutritional Biochemistry;2020-02